Foreword |
|
xx | |
Preface |
|
xxi | |
Acknowledgments |
|
xxv | |
Reviewers |
|
xxvi | |
Contributors |
|
xxviii | |
Select Abbreviations Used |
|
xxxi | |
|
SECTION ONE INTRODUCTION TO HEMATOLOGY |
|
|
1 | (24) |
|
|
1 | (6) |
|
|
2 | (1) |
|
|
2 | (1) |
|
|
2 | (1) |
|
Reference Intervals for Blood Cell Concentration |
|
|
3 | (1) |
|
|
3 | (1) |
|
|
3 | (1) |
|
Laboratory Testing in the Investigation of a Hematologic Problem |
|
|
3 | (2) |
|
|
5 | (1) |
|
|
5 | (1) |
|
|
6 | (1) |
|
|
6 | (1) |
|
Chapter 2 Cellular Homeostasis |
|
|
7 | (18) |
|
|
8 | (1) |
|
|
8 | (1) |
|
|
8 | (2) |
|
|
8 | (1) |
|
|
9 | (1) |
|
|
9 | (1) |
|
Cellular Metabolism: DNA Duplication, Transcription, Translation |
|
|
10 | (3) |
|
Control of Gene Expression |
|
|
11 | (1) |
|
Protein Synthesis and Processing |
|
|
11 | (1) |
|
|
12 | (1) |
|
Tissue Homeostasis: Proliferation, Differentiation, and Apoptosis |
|
|
13 | (8) |
|
Proliferation: The Cell Cycle |
|
|
13 | (3) |
|
|
16 | (1) |
|
|
16 | (5) |
|
Abnormal Tissue Homeostasis and Cancer |
|
|
21 | (1) |
|
|
21 | (1) |
|
|
21 | (2) |
|
|
23 | (1) |
|
|
23 | (2) |
|
SECTION TWO THE HEMATOPOIETIC SYSTEM |
|
|
25 | (153) |
|
Chapter 3 STRUCTURE AND FUNCTION OF HEMATOPOIETIC ORGANS |
|
|
25 | (12) |
|
|
26 | (1) |
|
|
26 | (1) |
|
Development of Hematopoiesis |
|
|
26 | (1) |
|
|
27 | (6) |
|
|
27 | (3) |
|
|
30 | (1) |
|
|
30 | (3) |
|
|
33 | (1) |
|
Mucosa-Associated Lymphoid Tissue (MALT) |
|
|
34 | (1) |
|
|
34 | (1) |
|
|
34 | (1) |
|
|
35 | (1) |
|
|
36 | (1) |
|
|
36 | (1) |
|
|
37 | (21) |
|
|
38 | (1) |
|
|
38 | (1) |
|
|
38 | (6) |
|
Hematopoietic Precursor Cells |
|
|
38 | (6) |
|
Cytokines and the Control of Hematopoiesis |
|
|
44 | (5) |
|
|
44 | (1) |
|
Characteristics of Growth Factors |
|
|
44 | (5) |
|
Cytokine Receptors, Signaling Pathways, and Transcription Factors |
|
|
49 | (3) |
|
|
49 | (1) |
|
|
50 | (1) |
|
|
50 | (1) |
|
Clinical Use of Hematopoietic Growth Factors |
|
|
51 | (1) |
|
Hematopoietic Microenvironment |
|
|
52 | (2) |
|
Components of the Hematopoietic Microenvironment |
|
|
52 | (1) |
|
Hematopoietic Microenvironment Niches |
|
|
52 | (2) |
|
|
54 | (1) |
|
|
54 | (2) |
|
|
56 | (1) |
|
|
56 | (2) |
|
Chapter 5 The Erythrocyte |
|
|
58 | (19) |
|
|
59 | (1) |
|
|
59 | (1) |
|
Erythropoiesis and Red Blood Cell Maturation |
|
|
59 | (4) |
|
Erythroid Progenitor Cells |
|
|
59 | (1) |
|
|
60 | (2) |
|
Characteristics of Cell Maturation |
|
|
62 | (1) |
|
|
63 | (1) |
|
|
63 | (5) |
|
|
64 | (1) |
|
|
64 | (3) |
|
|
67 | (1) |
|
|
68 | (2) |
|
|
68 | (1) |
|
Hexose Monophosphate (HMP) Shunt |
|
|
68 | (2) |
|
Methemoglobin Reductase Pathway |
|
|
70 | (1) |
|
|
70 | (1) |
|
|
70 | (2) |
|
Erythrocyte Concentration |
|
|
71 | (1) |
|
Regulation of Erythrocyte Production |
|
|
71 | (1) |
|
|
72 | (1) |
|
|
73 | (1) |
|
|
73 | (2) |
|
|
75 | (1) |
|
|
75 | (1) |
|
|
75 | (2) |
|
|
77 | (20) |
|
|
78 | (1) |
|
|
78 | (1) |
|
|
79 | (2) |
|
|
81 | (2) |
|
|
81 | (1) |
|
|
81 | (2) |
|
Regulation of Hemoglobin Synthesis |
|
|
83 | (1) |
|
|
84 | (1) |
|
|
84 | (1) |
|
|
84 | (1) |
|
|
84 | (1) |
|
|
84 | (1) |
|
|
85 | (5) |
|
|
85 | (3) |
|
|
88 | (1) |
|
Nitric Oxide and Hemoglobin |
|
|
89 | (1) |
|
Artificial Oxygen Carriers |
|
|
89 | (1) |
|
|
90 | (2) |
|
Extravascular Destruction |
|
|
90 | (1) |
|
Intravascular Destruction |
|
|
91 | (1) |
|
Acquired Nonfunctional Hemoglobins |
|
|
92 | (2) |
|
|
92 | (1) |
|
|
93 | (1) |
|
|
93 | (1) |
|
|
94 | (1) |
|
|
94 | (2) |
|
|
96 | (1) |
|
|
96 | (1) |
|
Chapter 7 Granulocytes And Monocytes |
|
|
97 | (25) |
|
|
98 | (1) |
|
|
98 | (1) |
|
Leukocyte Concentration in the Peripheral Blood |
|
|
99 | (1) |
|
Leukocyte Surface Markers |
|
|
100 | (1) |
|
|
100 | (1) |
|
|
100 | (10) |
|
Differentiation, Maturation, and Morphology |
|
|
100 | (4) |
|
Distribution, Concentration, and Kinetics |
|
|
104 | (2) |
|
|
106 | (4) |
|
|
110 | (2) |
|
Differentiation, Maturation, and Morphology |
|
|
110 | (2) |
|
Distribution, Concentration, and Kinetics |
|
|
112 | (1) |
|
|
112 | (1) |
|
|
112 | (1) |
|
Differentiation, Maturation, and Morphology |
|
|
113 | (1) |
|
Concentration, Distribution, and Destruction |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
113 | (2) |
|
Differentiation, Maturation, and Morphology |
|
|
114 | (1) |
|
Distribution, Concentration, and Kinetics |
|
|
115 | (1) |
|
|
115 | (2) |
|
|
117 | (1) |
|
|
117 | (3) |
|
|
120 | (1) |
|
|
120 | (2) |
|
|
122 | (22) |
|
|
123 | (1) |
|
|
123 | (1) |
|
|
124 | (1) |
|
|
125 | (7) |
|
|
125 | (4) |
|
|
129 | (3) |
|
|
132 | (1) |
|
Natural Killer T(NKT) Cells |
|
|
132 | (1) |
|
Lymphocyte Identification and Morphology |
|
|
132 | (4) |
|
Morphology of Immature Lymphocytes |
|
|
133 | (2) |
|
Morphology of Activated Lymphocytes |
|
|
135 | (1) |
|
Lymphocyte Distribution, Concentration, and Kinetics |
|
|
136 | (1) |
|
|
136 | (4) |
|
B Lymphocytes (Humoral Immunity) |
|
|
136 | (1) |
|
T Lymphocytes (Cell-Mediated Immunity) |
|
|
137 | (1) |
|
|
138 | (1) |
|
Adhesion Molecules of the Adaptive Immune Response |
|
|
139 | (1) |
|
Aging and Lymphocyte Function |
|
|
139 | (1) |
|
|
139 | (1) |
|
|
140 | (1) |
|
|
141 | (1) |
|
|
142 | (1) |
|
|
142 | (2) |
|
|
144 | (10) |
|
|
145 | (1) |
|
|
145 | (1) |
|
Peripheral Blood Platelets |
|
|
145 | (1) |
|
|
145 | (1) |
|
Quantitative Platelet Evaluation |
|
|
146 | (1) |
|
|
146 | (5) |
|
|
146 | (3) |
|
|
149 | (2) |
|
|
151 | (1) |
|
|
151 | (1) |
|
|
152 | (1) |
|
|
152 | (2) |
|
Chapter 10 The Complete Blood Count And Peripheral Blood Smear Evaluation |
|
|
154 | (24) |
|
|
155 | (1) |
|
|
155 | (1) |
|
Pre-Examination Phase of the CBC |
|
|
156 | (1) |
|
Examination Phase of the CBC |
|
|
156 | (17) |
|
|
156 | (4) |
|
The Peripheral Blood Smear |
|
|
160 | (12) |
|
Clinical Laboratory Professional's Review of CBC Data |
|
|
172 | (1) |
|
Post-Examination Phase of the CBC |
|
|
173 | (1) |
|
Physiologic Variation in Hematologic Parameters |
|
|
173 | (1) |
|
CBC Variations in Newborns and Children |
|
|
173 | (1) |
|
CBC Variations Between Ethnic Groups and Sexes, in Elderly People, and by Geographic Location |
|
|
173 | (1) |
|
|
174 | (1) |
|
|
174 | (2) |
|
|
176 | (1) |
|
|
177 | (1) |
|
SECTION THREE THE ANEMIAS |
|
|
178 | (210) |
|
Chapter 11 Introduction To Anemia |
|
|
178 | (20) |
|
|
179 | (1) |
|
|
179 | (1) |
|
|
180 | (1) |
|
Interpretation of Abnormal Hemoglobin Concentrations |
|
|
180 | (1) |
|
|
181 | (1) |
|
Increase in Oxygenated Blood Flow |
|
|
181 | (1) |
|
Increase in Oxygen Utilization by Tissue |
|
|
181 | (1) |
|
|
181 | (7) |
|
|
181 | (1) |
|
|
182 | (1) |
|
|
183 | (5) |
|
Classification of Anemias |
|
|
188 | (6) |
|
Morphologic Classification |
|
|
188 | (1) |
|
Functional Classification |
|
|
188 | (4) |
|
Classification Using the Red Cell Distribution Width |
|
|
192 | (1) |
|
Laboratory Testing Schemas for Anemia Diagnosis |
|
|
193 | (1) |
|
|
194 | (1) |
|
|
195 | (2) |
|
|
197 | (1) |
|
|
197 | (1) |
|
Chapter 12 Anemias Of Disordered Iron Metabolism And Heme Synthesis |
|
|
198 | (33) |
|
|
199 | (1) |
|
|
200 | (1) |
|
|
200 | (9) |
|
|
200 | (1) |
|
|
201 | (1) |
|
|
202 | (2) |
|
|
204 | (1) |
|
Physiological Regulation of Iron Balance |
|
|
204 | (4) |
|
|
208 | (1) |
|
Laboratory Assessment of Iron |
|
|
209 | (1) |
|
|
209 | (1) |
|
|
210 | (4) |
|
|
210 | (1) |
|
|
210 | (1) |
|
|
211 | (1) |
|
|
211 | (1) |
|
|
212 | (2) |
|
|
214 | (1) |
|
Anemia of Chronic Disease |
|
|
214 | (2) |
|
|
214 | (1) |
|
|
215 | (1) |
|
|
215 | (1) |
|
Anemias Associated with Abnormal Heme Synthesis |
|
|
216 | (4) |
|
|
216 | (4) |
|
|
220 | (2) |
|
Hereditary Hemochromatosis |
|
|
221 | (1) |
|
Secondary Hemochromatosis |
|
|
222 | (1) |
|
|
222 | (1) |
|
|
222 | (3) |
|
|
223 | (1) |
|
|
224 | (1) |
|
|
225 | (1) |
|
|
225 | (1) |
|
|
225 | (2) |
|
|
227 | (2) |
|
|
229 | (1) |
|
|
229 | (2) |
|
Chapter 13 Hemoglobinopathies: Qualitative Defects |
|
|
231 | (20) |
|
|
232 | (1) |
|
|
232 | (1) |
|
Structural Hemoglobin Variants |
|
|
233 | (3) |
|
Identification of Hemoglobin Variants |
|
|
233 | (1) |
|
|
234 | (1) |
|
|
235 | (1) |
|
|
235 | (1) |
|
|
236 | (5) |
|
|
236 | (1) |
|
|
237 | (2) |
|
|
239 | (1) |
|
|
240 | (1) |
|
|
241 | (1) |
|
|
241 | (1) |
|
|
241 | (1) |
|
|
242 | (1) |
|
|
243 | (1) |
|
|
243 | (1) |
|
Unstable Hemoglobin Variants |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
245 | (1) |
|
Hemoglobin Variants with Altered Oxygen Affinity |
|
|
245 | (2) |
|
Hemoglobin Variants with Increased Oxygen Affinity |
|
|
245 | (1) |
|
Hemoglobin Variants with Decreased Oxygen Affinity |
|
|
245 | (1) |
|
|
246 | (1) |
|
|
247 | (1) |
|
|
247 | (2) |
|
|
249 | (1) |
|
|
249 | (2) |
|
|
251 | (26) |
|
|
252 | (1) |
|
|
252 | (5) |
|
Thalassemia Versus Hemoglobinopathy |
|
|
253 | (1) |
|
Genetic Defects in Thalassemia |
|
|
254 | (1) |
|
|
254 | (1) |
|
|
255 | (1) |
|
|
255 | (1) |
|
|
256 | (1) |
|
|
257 | (4) |
|
|
257 | (1) |
|
α-Thalassemia Major (α0/α0 or α-thal-1/α-thal-1; Hydrops Fetalis) |
|
|
257 | (2) |
|
Hemoglobin H Disease (α0/α+ or α-thal-1/α-thal-2) |
|
|
259 | (1) |
|
α-Thalassemia Minor (α-thal-2/α-thal-2 [ a+/a+], or α-thal-1/normal [ α0/α]) |
|
|
260 | (1) |
|
Silent Carrier (α-thal-2/normal; α+/ α) |
|
|
261 | (1) |
|
|
261 | (6) |
|
|
261 | (1) |
|
β-Thalassemia Major (β0/β0, β0/β+, β+/ β+) |
|
|
262 | (3) |
|
β-Thalassemia Minor (β0/β or β+/ β) |
|
|
265 | (1) |
|
β-Thalassemia Intermedia (β+/ β+, β0/β+, β0/β) |
|
|
266 | (1) |
|
β-Thalassemia Minima (βSC/β) |
|
|
267 | (1) |
|
Other Thalassemias and Thalassemia-Like Conditions |
|
|
267 | (4) |
|
|
267 | (1) |
|
|
267 | (1) |
|
Hemoglobin Constant Spring |
|
|
267 | (1) |
|
Hereditary Persistence of Fetal Hemoglobin (HPFH) |
|
|
268 | (1) |
|
|
269 | (1) |
|
|
270 | (1) |
|
Differential Diagnosis of Thalassemia |
|
|
271 | (1) |
|
|
272 | (1) |
|
|
272 | (2) |
|
|
274 | (1) |
|
|
274 | (3) |
|
Chapter 15 Megaloblastic And Nonmegaloblastic Macrocytic Anemias |
|
|
277 | (25) |
|
|
279 | (1) |
|
|
279 | (1) |
|
|
279 | (17) |
|
|
280 | (1) |
|
|
281 | (2) |
|
|
283 | (4) |
|
|
287 | (7) |
|
Other Megaloblastic Anemias |
|
|
294 | (2) |
|
Macrocytic Anemia Without Megaloblastosis |
|
|
296 | (2) |
|
|
296 | (1) |
|
|
296 | (2) |
|
Stimulated Erythropoiesis |
|
|
298 | (1) |
|
|
298 | (1) |
|
|
298 | (1) |
|
|
299 | (1) |
|
|
300 | (1) |
|
|
301 | (1) |
|
Chapter 16 Hypoproliferative Anemias |
|
|
302 | (15) |
|
|
303 | (1) |
|
|
303 | (1) |
|
|
303 | (7) |
|
|
304 | (1) |
|
|
304 | (1) |
|
Classification and Etiology |
|
|
304 | (3) |
|
|
307 | (1) |
|
|
307 | (1) |
|
|
308 | (1) |
|
Differentiation of Aplastic Anemia from other Causes of Pancytopenia |
|
|
309 | (1) |
|
|
310 | (2) |
|
Acquired Acute Pure Red Cell Aplasia |
|
|
310 | (1) |
|
Chronic Acquired Pure Red Cell Aplasia |
|
|
311 | (1) |
|
Diamond-Blackfan Syndrome |
|
|
311 | (1) |
|
Other Hypoproliferative Anemias |
|
|
312 | (1) |
|
|
312 | (1) |
|
|
313 | (1) |
|
|
313 | (1) |
|
|
314 | (2) |
|
|
316 | (1) |
|
|
316 | (1) |
|
Chapter 17 Hemolytic Anemia: Membrane Defects |
|
|
317 | (17) |
|
|
318 | (1) |
|
|
318 | (1) |
|
|
318 | (2) |
|
Skeletal Protein Abnormalities |
|
|
318 | (2) |
|
|
320 | (3) |
|
|
320 | (1) |
|
|
321 | (1) |
|
|
321 | (2) |
|
Identification of Deficient/Defective Membrane Protein |
|
|
323 | (1) |
|
|
323 | (1) |
|
Hereditary Elliptocytosis |
|
|
323 | (2) |
|
|
323 | (1) |
|
|
324 | (1) |
|
|
324 | (1) |
|
|
325 | (1) |
|
Hereditary Pyropoikilocytosis (HPP) |
|
|
325 | (1) |
|
|
325 | (1) |
|
|
325 | (1) |
|
|
325 | (1) |
|
|
325 | (1) |
|
Hereditary Stomatocytosis Syndromes |
|
|
326 | (1) |
|
|
326 | (1) |
|
|
326 | (1) |
|
|
327 | (1) |
|
Abnormal Membrane Lipid Composition: Acanthocytosis |
|
|
327 | (1) |
|
|
327 | (1) |
|
Abetalipoproteinemia (Hereditary Acanthocytosis) |
|
|
327 | (1) |
|
Lecithin-Cholesterol Acyl Transferase (LCAT) Deficiency |
|
|
328 | (1) |
|
|
328 | (1) |
|
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
|
328 | (2) |
|
|
328 | (1) |
|
|
329 | (1) |
|
|
329 | (1) |
|
|
330 | (1) |
|
|
330 | (1) |
|
|
330 | (3) |
|
|
333 | (1) |
|
|
333 | (1) |
|
Chapter 18 Hemolytic Anemia: Enzyme Deficiencies |
|
|
334 | (14) |
|
|
335 | (1) |
|
|
335 | (2) |
|
Hexose Monophosphate Shunt |
|
|
336 | (1) |
|
|
336 | (1) |
|
Clinical and Laboratory Findings in Erythrocyte Enzyme Deficiencies |
|
|
336 | (1) |
|
|
337 | (1) |
|
Glucose-6-Phosphate Dehydrogenase Deficiency |
|
|
337 | (4) |
|
|
337 | (1) |
|
|
338 | (1) |
|
Females with G6PD Deficiency |
|
|
338 | (1) |
|
|
339 | (1) |
|
|
340 | (1) |
|
|
341 | (1) |
|
|
341 | (1) |
|
Other Defects and Deficiencies of the HMP Shunt and GSH Metabolism |
|
|
341 | (1) |
|
Pyruvate Kinase (PK) Deficiency |
|
|
342 | (1) |
|
|
342 | (1) |
|
|
342 | (1) |
|
|
342 | (1) |
|
|
343 | (1) |
|
Other Enzyme Deficiencies in the Glycolytic Pathway |
|
|
343 | (1) |
|
Abnormal Erythrocyte Nucleotide Metabolism |
|
|
343 | (1) |
|
|
344 | (1) |
|
|
344 | (2) |
|
|
346 | (1) |
|
|
346 | (2) |
|
Chapter 19 Hemolytic Anemia: Immune Anemias |
|
|
348 | (24) |
|
|
349 | (1) |
|
|
349 | (1) |
|
Classification of Immune Hemolytic Anemias |
|
|
350 | (1) |
|
Sites and Factors that Affect Hemolysis |
|
|
351 | (1) |
|
|
352 | (1) |
|
|
352 | (1) |
|
Complement-Mediated Hemolysis |
|
|
352 | (1) |
|
|
353 | (1) |
|
Laboratory Identification of Sensitized Red Cells |
|
|
353 | (2) |
|
|
354 | (1) |
|
Indirect Antiglobulin Test |
|
|
354 | (1) |
|
|
354 | (1) |
|
Positive DAT in Normal Individuals |
|
|
355 | (1) |
|
Autoimmune Hemolytic Anemias (AIHA) |
|
|
355 | (8) |
|
Warm Autoimmune Hemolytic Anemia |
|
|
355 | (3) |
|
Cold Autoimmune Hemolytic Anemia |
|
|
358 | (2) |
|
Paroxysmal Cold Hemoglobinuria |
|
|
360 | (1) |
|
|
361 | (1) |
|
Drug-Induced Hemolytic Anemias |
|
|
361 | (2) |
|
Alloimmune Hemolytic Anemia |
|
|
363 | (4) |
|
Hemolytic Transfusion Reactions |
|
|
363 | (2) |
|
Hemolytic Disease of the Fetus and Newborn (HDFN) |
|
|
365 | (2) |
|
|
367 | (1) |
|
|
368 | (2) |
|
|
370 | (1) |
|
|
370 | (2) |
|
Chapter 20 Hemolytic Anemia: Nonimmune Defects |
|
|
372 | (16) |
|
|
373 | (1) |
|
|
373 | (1) |
|
Hemolytic Anemia Caused by Physical Injury to the Erythrocyte |
|
|
373 | (7) |
|
Microangiopathic Hemolytic Anemia |
|
|
374 | (6) |
|
Other Erythrocyte Physical Trauma Resulting in Hemolytic Anemia |
|
|
380 | (1) |
|
Hemolytic Anemias Caused by Antagonists in the Blood |
|
|
380 | (3) |
|
|
380 | (2) |
|
|
382 | (1) |
|
|
383 | (1) |
|
|
383 | (1) |
|
|
383 | (2) |
|
|
385 | (1) |
|
|
385 | (3) |
|
SECTION FOUR Nonmalignant Disorders Of Leukocytes |
|
|
388 | (37) |
|
Chapter 21 Nonmalignant Disorders Of Leukocytes: Granulocytes And Monocytes |
|
|
388 | (20) |
|
|
389 | (1) |
|
|
390 | (1) |
|
|
390 | (10) |
|
|
390 | (5) |
|
Qualitative or Morphologic Abnormalities |
|
|
395 | (5) |
|
|
400 | (1) |
|
Nonclonal (Reactive) Eosinophilia |
|
|
400 | (1) |
|
Clonal (Neoplastic) Eosinophilia |
|
|
401 | (1) |
|
Basophil and Mast Cell Disorders |
|
|
401 | (1) |
|
Monocyte/Macrophage Disorders |
|
|
402 | (2) |
|
|
402 | (1) |
|
|
402 | (2) |
|
|
404 | (1) |
|
|
405 | (2) |
|
|
407 | (1) |
|
|
407 | (1) |
|
Chapter 22 Nonmalignant Lymphocyte Disorders |
|
|
408 | (17) |
|
|
409 | (1) |
|
|
409 | (1) |
|
|
410 | (5) |
|
|
411 | (2) |
|
|
413 | (1) |
|
|
413 | (1) |
|
The Reactive Lymphocytosis Process |
|
|
413 | (1) |
|
|
413 | (1) |
|
Persistent Polyclonal B-Cell Lymphocytosis |
|
|
414 | (1) |
|
Other Conditions Associated with Lymphocytosis |
|
|
414 | (1) |
|
|
414 | (1) |
|
|
415 | (6) |
|
Immune Deficiency Disorders |
|
|
415 | (6) |
|
|
421 | (1) |
|
|
421 | (3) |
|
|
424 | (1) |
|
|
424 | (1) |
|
SECTION FIVE NEOPLASTIC HEMATOLOGIC DISORDERS |
|
|
425 | (147) |
|
Chapter 23 Introduction To Hematopoietic Neoplasms |
|
|
425 | (21) |
|
|
426 | (1) |
|
|
427 | (1) |
|
|
428 | (5) |
|
|
428 | (1) |
|
Molecular Basis of Cancer |
|
|
429 | (2) |
|
|
431 | (2) |
|
|
433 | (1) |
|
|
433 | (1) |
|
|
433 | (1) |
|
Hematopoietic Neoplasm Classification |
|
|
434 | (2) |
|
|
434 | (1) |
|
|
435 | (1) |
|
Laboratory Procedures for Diagnosing and Classifying Neoplasms |
|
|
436 | (2) |
|
|
436 | (1) |
|
|
437 | (1) |
|
|
438 | (1) |
|
Prognosis and Treatment of Neoplastic Disorders |
|
|
438 | (3) |
|
|
438 | (1) |
|
|
439 | (2) |
|
|
441 | (1) |
|
|
442 | (2) |
|
|
444 | (1) |
|
|
445 | (1) |
|
Chapter 24 Myeloproliferative Neoplasms |
|
|
446 | (33) |
|
|
447 | (1) |
|
|
448 | (1) |
|
Part I Overview of Myeloproliferative Neoplasms (MPNs) |
|
|
448 | (1) |
|
|
448 | (1) |
|
|
449 | (1) |
|
|
450 | (1) |
|
Part II Subgroups of MPNs |
|
|
450 | (1) |
|
Chronic Myelogenous Leukemia (CML) |
|
|
450 | (7) |
|
Etiology and Pathophysiology |
|
|
451 | (2) |
|
|
453 | (1) |
|
|
453 | (1) |
|
|
454 | (1) |
|
|
455 | (1) |
|
|
456 | (1) |
|
Chronic Neutrophilic Leukemia (CNL) |
|
|
457 | (1) |
|
Etiology and Pathophysiology |
|
|
457 | (1) |
|
|
457 | (1) |
|
|
458 | (1) |
|
|
458 | (1) |
|
|
458 | (1) |
|
Essential Thrombocythemia (ET) |
|
|
458 | (3) |
|
Etiology and Pathophysiology |
|
|
458 | (1) |
|
|
459 | (1) |
|
|
459 | (1) |
|
|
460 | (1) |
|
|
460 | (1) |
|
|
461 | (6) |
|
|
461 | (1) |
|
Etiology and Pathophysiology |
|
|
462 | (1) |
|
|
463 | (1) |
|
|
463 | (1) |
|
|
464 | (1) |
|
|
465 | (1) |
|
|
465 | (2) |
|
Primary Myelofibrosis (PMF) |
|
|
467 | (3) |
|
Etiology and Pathophysiology |
|
|
467 | (1) |
|
|
467 | (1) |
|
|
468 | (1) |
|
|
469 | (1) |
|
|
469 | (1) |
|
Myeloproliferative Neoplasm, Unclassifiable (MPN, U) |
|
|
470 | (1) |
|
|
470 | (1) |
|
|
470 | (3) |
|
Myeloid and Lymphoid Neoplasms Associated with Eosinophilia and PDGFRA, PDGFRB, or FGFR1 Mutations |
|
|
471 | (1) |
|
Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL-NOS) |
|
|
472 | (1) |
|
Idiopathic Hypereosinophilic Syndrome (I-HES) |
|
|
473 | (1) |
|
Mast Cell Disease (Mastocytosis) |
|
|
473 | (1) |
|
|
474 | (1) |
|
|
474 | (3) |
|
|
477 | (1) |
|
|
477 | (2) |
|
Chapter 25 Myelodysplastic Syndromes |
|
|
479 | (21) |
|
|
480 | (1) |
|
|
480 | (1) |
|
|
481 | (2) |
|
Cytogenetics, Epigenetics, and Single Gene Mutations |
|
|
481 | (1) |
|
Proliferation Abnormalities |
|
|
482 | (1) |
|
|
483 | (1) |
|
|
483 | (1) |
|
|
483 | (4) |
|
|
483 | (2) |
|
|
485 | (1) |
|
|
486 | (1) |
|
Other Laboratory Findings |
|
|
486 | (1) |
|
Blast and Precursor Cell Classification |
|
|
487 | (2) |
|
|
487 | (1) |
|
|
487 | (1) |
|
|
488 | (1) |
|
Cytochemical and Immunological Identification of Blasts |
|
|
489 | (1) |
|
|
489 | (1) |
|
Description of Subgroups of MDS |
|
|
489 | (3) |
|
Refractory Cytopenia with Unilineage Dysplasia (RCUD) |
|
|
490 | (1) |
|
Refractory Anemia with Ring Sideroblasts (RARS) |
|
|
491 | (1) |
|
Refractory Cytopenia with Multilineage Dysplasia (RCMD) |
|
|
491 | (1) |
|
Refractory Anemia with Excess Blasts (RAEBs) |
|
|
491 | (1) |
|
MDS Associated with Isolated del(5q) |
|
|
491 | (1) |
|
Myelodysplastic Syndrome, Unclassifiable |
|
|
491 | (1) |
|
|
491 | (1) |
|
|
492 | (1) |
|
|
492 | (1) |
|
|
492 | (1) |
|
Therapy-Related Myelodysplasia |
|
|
492 | (1) |
|
|
493 | (1) |
|
|
494 | (1) |
|
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) |
|
|
494 | (2) |
|
Chronic Myelomonocytic Leukemia |
|
|
494 | (1) |
|
Atypical Chronic Myeloid Leukemia (aCML, BCR/ABL1-) |
|
|
495 | (1) |
|
Juvenile Myelomonocytic Leukemia |
|
|
496 | (1) |
|
Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U) |
|
|
496 | (1) |
|
|
496 | (1) |
|
|
497 | (1) |
|
|
498 | (1) |
|
|
499 | (1) |
|
Chapter 26 Acute Myeloid Leukemias |
|
|
500 | (22) |
|
|
501 | (1) |
|
|
501 | (1) |
|
Etiology and Pathophysiology |
|
|
502 | (1) |
|
|
502 | (1) |
|
|
502 | (1) |
|
|
503 | (1) |
|
Other Laboratory Findings |
|
|
503 | (1) |
|
|
503 | (15) |
|
Identification of Cell Lineage |
|
|
504 | (1) |
|
Assessment of Bone Marrow |
|
|
505 | (3) |
|
WHO Classification of AML |
|
|
508 | (10) |
|
|
518 | (1) |
|
|
518 | (1) |
|
|
519 | (1) |
|
|
520 | (1) |
|
|
521 | (1) |
|
Chapter 27 Precursor Lymphoid Neoplasms |
|
|
522 | (13) |
|
|
523 | (1) |
|
|
523 | (1) |
|
Etiology and Pathogenesis |
|
|
523 | (1) |
|
|
524 | (1) |
|
|
524 | (2) |
|
|
524 | (1) |
|
|
525 | (1) |
|
|
525 | (1) |
|
Other Laboratory Findings |
|
|
525 | (1) |
|
Identification of Cell Lineage |
|
|
526 | (1) |
|
Morphology and Cytochemistry |
|
|
526 | (1) |
|
Terminal Deoxynucleotidyl Transferase (TdT) |
|
|
526 | (1) |
|
|
526 | (1) |
|
|
527 | (1) |
|
|
527 | (1) |
|
|
527 | (4) |
|
B-Lymphoblastic Leukemia/Lymphoma |
|
|
527 | (2) |
|
T-Lymphoblastic Leukemia/Lymphoma |
|
|
529 | (1) |
|
Acute Leukemias of Ambiguous Lineage |
|
|
530 | (1) |
|
|
531 | (1) |
|
|
531 | (1) |
|
|
532 | (2) |
|
|
534 | (1) |
|
|
534 | (1) |
|
Chapter 28 Mature Lymphoid Neoplasms |
|
|
535 | (22) |
|
|
536 | (1) |
|
|
537 | (1) |
|
Etiology and Pathogenesis |
|
|
537 | (1) |
|
|
537 | (1) |
|
Inherited genetic Factors |
|
|
537 | (1) |
|
|
537 | (1) |
|
Diagnosis and Classification |
|
|
537 | (2) |
|
|
539 | (10) |
|
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
539 | (1) |
|
B-Cell Prolymphocyte Leukemia |
|
|
540 | (1) |
|
|
541 | (1) |
|
|
541 | (2) |
|
Mantle Cell Lymphoma (MCL) |
|
|
543 | (1) |
|
Extranodal Marginal Zone Lymphoma of Mucosa Associated Lymphoid Tissue |
|
|
544 | (1) |
|
Lymphoplasmacytic Lymphoma |
|
|
544 | (1) |
|
Diffuse Large B-Cell Lymphoma |
|
|
545 | (1) |
|
|
545 | (1) |
|
|
546 | (3) |
|
Mature T- and NK-Cell Neoplasms |
|
|
549 | (2) |
|
T-Cell Prolymphocytic Leukemia |
|
|
549 | (1) |
|
T-Cell Large Granular Lymphocytic (T-LGL) Leukemia |
|
|
550 | (1) |
|
|
550 | (1) |
|
Anaplastic Large Cell Lymphoma (ALCL) |
|
|
550 | (1) |
|
Peripheral T-Cell Lymphoma, Not Otherwise Specified (NOS) |
|
|
551 | (1) |
|
|
551 | (2) |
|
|
553 | (1) |
|
|
554 | (2) |
|
|
556 | (1) |
|
|
556 | (1) |
|
Chapter 29 Hematopoietic Stem Cell Transplantation |
|
|
557 | (15) |
|
|
558 | (1) |
|
|
558 | (1) |
|
Origin and Differentiation of Hematopoietic Stem Cells |
|
|
559 | (1) |
|
Sources of Hematopoietic Stem Cells and Types of Stem Cell Transplants |
|
|
559 | (2) |
|
Allogeneic Stem Cell Transplantation |
|
|
559 | (1) |
|
Autologous Stem Cell Transplantation |
|
|
560 | (1) |
|
Umbilical Cord Stem Cell Transplantation |
|
|
560 | (1) |
|
Collection and Processing of Hematopoietic Stem Cells |
|
|
561 | (1) |
|
|
561 | (1) |
|
|
561 | (1) |
|
Umbilical Cord Blood (UCB) |
|
|
562 | (1) |
|
|
562 | (1) |
|
Cryopreservation and Storage of Hematopoietic Stem Cells |
|
|
562 | (1) |
|
Infusion of Hematopoietic Stem Cells |
|
|
562 | (1) |
|
Quantitation of Hematopoietic Stem Cells |
|
|
562 | (2) |
|
Determination of Mononuclear Cell Count |
|
|
562 | (1) |
|
CD34 Enumeration by Flow Cytometry |
|
|
563 | (1) |
|
Cell Culture for Colony Forming Units |
|
|
563 | (1) |
|
Collection Target for Stem Cells |
|
|
564 | (1) |
|
Hematopoietic Engraftment |
|
|
564 | (1) |
|
Evidence of Initial Engraftment |
|
|
564 | (1) |
|
Evidence of Long-Term Engraftment |
|
|
564 | (1) |
|
Role of the Clinical Laboratory Professional in Stem Cell Transplantation |
|
|
564 | (1) |
|
Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect |
|
|
565 | (2) |
|
Complications Associated with Stem Cell Transplantation |
|
|
567 | (1) |
|
|
567 | (1) |
|
|
567 | (1) |
|
Increased Availability and Success of Stem Cell Transplantation |
|
|
568 | (1) |
|
|
568 | (1) |
|
|
568 | (1) |
|
|
568 | (2) |
|
|
570 | (1) |
|
|
570 | (2) |
|
|
572 | (36) |
|
Chapter 30 Morphologic Analysis Of Body Fluids In The Hematology Laboratory |
|
|
572 | (36) |
|
|
573 | (1) |
|
|
574 | (1) |
|
|
574 | (4) |
|
|
574 | (1) |
|
|
575 | (2) |
|
|
577 | (1) |
|
Bronchoalveolar Lavage (BAL) |
|
|
577 | (1) |
|
Hematologic Analysis of Body Fluids |
|
|
578 | (22) |
|
Specimen Collection and Handling |
|
|
578 | (1) |
|
|
578 | (1) |
|
|
579 | (3) |
|
Nucleated Cell Differential |
|
|
582 | (18) |
|
|
600 | (4) |
|
|
600 | (1) |
|
Amniotic Fluid Lamellar Body Counts |
|
|
600 | (1) |
|
|
601 | (3) |
|
|
604 | (1) |
|
|
604 | (2) |
|
|
606 | (1) |
|
|
606 | (2) |
|
|
608 | (174) |
|
Chapter 31 Primary Hemostasis |
|
|
608 | (24) |
|
|
609 | (1) |
|
|
609 | (1) |
|
Role of the Vascular System |
|
|
610 | (5) |
|
Structure of Blood Vessels |
|
|
610 | (1) |
|
Functions of Blood Vessels in Hemostasis |
|
|
611 | (2) |
|
Functions of Endothelial Cells |
|
|
613 | (2) |
|
|
615 | (13) |
|
|
615 | (5) |
|
|
620 | (8) |
|
Physiologic Controls of Platelet Activation |
|
|
628 | (1) |
|
|
628 | (1) |
|
|
629 | (1) |
|
|
630 | (1) |
|
|
630 | (2) |
|
Chapter 32 Secondary Hemostasis And Fibrinolysis |
|
|
632 | (31) |
|
|
633 | (1) |
|
|
634 | (1) |
|
|
634 | (1) |
|
|
635 | (3) |
|
Properties of the Blood Coagulation Factors |
|
|
635 | (2) |
|
Mechanism of Action of the Coagulation Factors |
|
|
637 | (1) |
|
Vitamin K-Dependent Coagulation Proteins |
|
|
637 | (1) |
|
Structure of the Blood Coagulation Proteins |
|
|
638 | (1) |
|
|
638 | (9) |
|
Complex Formation on Phosholipid Surfaces |
|
|
638 | (1) |
|
|
638 | (5) |
|
|
643 | (1) |
|
|
643 | (4) |
|
|
647 | (6) |
|
|
647 | (1) |
|
Plasminogen (PLG) and Plasmin (PLN) |
|
|
648 | (1) |
|
Activators of Fibrinolysis |
|
|
648 | (2) |
|
|
650 | (2) |
|
Inhibitors of Fibrinolysis |
|
|
652 | (1) |
|
|
653 | (5) |
|
|
653 | (1) |
|
|
653 | (1) |
|
Positive Feedback Amplification |
|
|
653 | (1) |
|
Negative Feedback Inhibition |
|
|
654 | (1) |
|
|
654 | (4) |
|
|
658 | (1) |
|
|
659 | (1) |
|
|
659 | (2) |
|
|
661 | (1) |
|
|
661 | (2) |
|
Chapter 33 Disorders Of Primary Hemostasis |
|
|
663 | (26) |
|
|
664 | (1) |
|
|
665 | (1) |
|
Diagnosis of Bleeding Disorders |
|
|
665 | (1) |
|
Clinical Manifestations of Bleeding Disorders |
|
|
665 | (1) |
|
Evaluation of a Patient with Abnormal Bleeding |
|
|
665 | (1) |
|
Disorders of the Vascular System |
|
|
666 | (3) |
|
Hereditary Disorders of the Vascular System |
|
|
667 | (1) |
|
Acquired Disorders of the Vascular System |
|
|
667 | (2) |
|
|
669 | (16) |
|
Quantitative Platelet Disorders |
|
|
669 | (10) |
|
Qualitative (Functional) Platelet Disorders |
|
|
679 | (6) |
|
|
685 | (1) |
|
|
685 | (2) |
|
|
687 | (1) |
|
|
687 | (2) |
|
Chapter 34 Disorders Of Secondary Hemostasis |
|
|
689 | (31) |
|
|
690 | (1) |
|
|
690 | (1) |
|
Disorders of the Proteins of Fibrin Formation |
|
|
691 | (22) |
|
Hereditary Disorders of Secondary Hemostasis |
|
|
692 | (14) |
|
Acquired Disorders of Hemostasis Associated with Bleeding |
|
|
706 | (7) |
|
|
713 | (1) |
|
Hemostasis in the Newborn |
|
|
713 | (2) |
|
Normal Hemostasis in the Newborn |
|
|
713 | (2) |
|
Common Bleeding Disorders in the Neonate |
|
|
715 | (1) |
|
|
715 | (1) |
|
|
716 | (2) |
|
|
718 | (1) |
|
|
718 | (2) |
|
|
720 | (30) |
|
|
721 | (1) |
|
|
722 | (1) |
|
|
722 | (2) |
|
|
722 | (1) |
|
|
723 | (1) |
|
Microparticles in Arterial and Venous Thrombosis |
|
|
724 | (1) |
|
|
724 | (15) |
|
|
725 | (6) |
|
Other Potential Genetic Risk Factors |
|
|
731 | (2) |
|
Acquired Thrombohemorrhagic Conditions |
|
|
733 | (6) |
|
Laboratory Testing in Patients with Suspected Thrombosis |
|
|
739 | (1) |
|
|
740 | (4) |
|
|
740 | (1) |
|
|
741 | (1) |
|
|
742 | (1) |
|
|
742 | (1) |
|
|
743 | (1) |
|
|
744 | (1) |
|
|
744 | (2) |
|
|
746 | (1) |
|
|
746 | (4) |
|
Chapter 36 Hemostasis: Laboratory Testing And Instrumentation |
|
|
750 | (32) |
|
|
752 | (1) |
|
|
752 | (1) |
|
Specimen Collection and Processing |
|
|
752 | (2) |
|
|
752 | (1) |
|
|
753 | (1) |
|
Laboratory Investigation of Primary Hemostasis |
|
|
754 | (3) |
|
|
754 | (1) |
|
Platelet Function Analyzers |
|
|
754 | (3) |
|
Laboratory Investigation of Secondary Hemostasis |
|
|
757 | (7) |
|
|
757 | (2) |
|
Tests to Identify a Specific Factor Deficiency |
|
|
759 | (5) |
|
Identification of Inhibitors |
|
|
764 | (3) |
|
Laboratory Investigation of the Fibrinolytic System |
|
|
766 | (1) |
|
|
766 | (1) |
|
Fibrin Degradation Products |
|
|
767 | (1) |
|
|
767 | (1) |
|
Laboratory Investigation of Hypercoagulable States |
|
|
767 | (3) |
|
|
768 | (1) |
|
Protein C/Activated Protein C (APC) |
|
|
768 | (1) |
|
|
769 | (1) |
|
Activated Protein C Resistance (APCR) |
|
|
769 | (1) |
|
|
769 | (1) |
|
Additional Testing for Thrombosis |
|
|
769 | (1) |
|
Laboratory Evaluation of Anticoagulant Therapy |
|
|
770 | (3) |
|
Oral Anticoagulant Therapy and the Prothrombin Time---INR Value |
|
|
771 | (1) |
|
Heparin Therapy Monitoring |
|
|
771 | (2) |
|
Molecular Markers of Hemostatic Activation |
|
|
773 | (1) |
|
Markers of Fibrin Formation and Fibrinolysis |
|
|
773 | (1) |
|
Laboratory Markers of Platelet Activation |
|
|
773 | (1) |
|
|
774 | (1) |
|
Thromboelastography (TEG) |
|
|
774 | (1) |
|
|
774 | (1) |
|
Calibrated Automated Thrombogran (CAT) |
|
|
774 | (1) |
|
Hemostasis Instrumentation |
|
|
774 | (3) |
|
Evolution of Hemostasis Testing |
|
|
774 | (1) |
|
Automated Hemostasis Analyzer Methodologies |
|
|
775 | (1) |
|
Point-of-Care (POC) Hemostasis Instrumentation |
|
|
776 | (1) |
|
|
777 | (1) |
|
|
777 | (2) |
|
|
779 | (1) |
|
|
779 | (3) |
|
SECTION EIGHT HEMATOLOGY PROCEDURES |
|
|
782 | (121) |
|
Chapter 37 Hematology Procedures |
|
|
782 | (33) |
|
|
784 | (1) |
|
Laboratory Testing Regulations |
|
|
784 | (1) |
|
Sample Collection: Phlebotomy |
|
|
785 | (3) |
|
|
785 | (1) |
|
|
786 | (1) |
|
|
787 | (1) |
|
|
787 | (1) |
|
|
787 | (1) |
|
Microscopy: the Microscope |
|
|
788 | (2) |
|
|
788 | (1) |
|
Phase-Contrast Microscopy |
|
|
789 | (1) |
|
|
789 | (1) |
|
|
789 | (1) |
|
Part I Routine Hematology Procedures |
|
|
790 | (1) |
|
Peripheral Blood Smear Preparation |
|
|
790 | (1) |
|
|
790 | (1) |
|
|
791 | (1) |
|
Peripheral Blood Smear Staining |
|
|
791 | (1) |
|
Peripheral Blood Smear Examination |
|
|
792 | (2) |
|
Cell Enumeration by Hemacytometer |
|
|
794 | (1) |
|
|
794 | (1) |
|
|
795 | (1) |
|
|
795 | (1) |
|
|
795 | (1) |
|
|
796 | (1) |
|
|
796 | (1) |
|
Erythrocyte Sedimentation Rate (ESR) |
|
|
797 | (1) |
|
|
798 | (1) |
|
Solubility Test for Hemoglobin S |
|
|
799 | (1) |
|
Part II Reflex Hematology Procedures |
|
|
800 | (1) |
|
Hemoglobin Electrophoresis |
|
|
800 | (1) |
|
Quantitation of Hemoglobin A2 |
|
|
801 | (1) |
|
Acid Elution for Hemoglobin F |
|
|
801 | (1) |
|
Quantitation of Hemoglobin F |
|
|
802 | (1) |
|
|
802 | (1) |
|
|
802 | (1) |
|
Heat Denaturation Test for Unstable Hemoglobin |
|
|
802 | (1) |
|
|
802 | (1) |
|
|
803 | (1) |
|
Donath-Landsteiner Test for Paroxysmal Cold Hemoglobinuria (PCH) |
|
|
804 | (1) |
|
|
804 | (1) |
|
Soluble Transferrin Receptor |
|
|
805 | (1) |
|
|
805 | (5) |
|
|
805 | (1) |
|
|
805 | (1) |
|
|
806 | (1) |
|
α-Naphthyl Esterase (Nonspecific Esterase) |
|
|
806 | (1) |
|
|
807 | (1) |
|
Leukocyte Alkaline Phosphatase |
|
|
807 | (1) |
|
Acid Phosphatase and Tartrate-Resistan Acid Phosphatase (TRAP) |
|
|
808 | (1) |
|
Terminal Deoxynucleotidyl Transferase |
|
|
808 | (1) |
|
|
809 | (1) |
|
Reticulin Stain and Masson's Trichrome Stain |
|
|
809 | (1) |
|
|
810 | (1) |
|
|
810 | (2) |
|
|
812 | (1) |
|
|
812 | (3) |
|
Chapter 38 Bone Marrow Examination |
|
|
815 | (14) |
|
|
816 | (1) |
|
|
816 | (1) |
|
Indications for Bone Marrow Evaluation |
|
|
816 | (1) |
|
|
817 | (1) |
|
Bone Marrow Processing for Examination |
|
|
818 | (1) |
|
Bone Marrow Aspirate Smears, Particle Preparation, and Clot Sections |
|
|
818 | (1) |
|
Touch Imprints and Core Biopsy |
|
|
819 | (1) |
|
Morphologic Interpretation of Bone Marrow |
|
|
819 | (5) |
|
|
819 | (2) |
|
|
821 | (1) |
|
Bone Marrow Particle Preparation and Clot and Core Biopsy |
|
|
821 | (1) |
|
Benign Lymphoid Aggregates versus Malignant Lymphoma |
|
|
821 | (2) |
|
|
823 | (1) |
|
Special Studies on Bone Marrow |
|
|
824 | (1) |
|
|
824 | (1) |
|
|
824 | (1) |
|
|
824 | (1) |
|
|
825 | (1) |
|
|
825 | (1) |
|
|
826 | (1) |
|
|
826 | (2) |
|
|
828 | (1) |
|
|
828 | (1) |
|
Chapter 39 Automation In Hematology |
|
|
829 | (24) |
|
|
830 | (1) |
|
|
830 | (1) |
|
Automated Blood Cell--Counting Instruments |
|
|
830 | (18) |
|
|
831 | (15) |
|
Light-Scattering Instruments |
|
|
846 | (2) |
|
|
848 | (1) |
|
|
849 | (2) |
|
|
851 | (1) |
|
|
851 | (2) |
|
Chapter 40 Flow Cytometry |
|
|
853 | (16) |
|
|
854 | (1) |
|
|
854 | (1) |
|
Principles of Flow Cytometry |
|
|
855 | (2) |
|
Isolation of Single Particles |
|
|
855 | (1) |
|
|
856 | (1) |
|
Detection of Fluorochromes |
|
|
856 | (1) |
|
|
857 | (1) |
|
Immunophenotyping by Flow Cytometry |
|
|
857 | (7) |
|
Specimen Requirements and Preparation for Immunophenotyping |
|
|
859 | (1) |
|
Isolation of Cells of Interest by Gating |
|
|
859 | (1) |
|
Diagnosis and Classification of Mature Lymphoid Neoplasms |
|
|
859 | (2) |
|
Diagnosis and Classification of Acute Leukemia |
|
|
861 | (2) |
|
Diagnosis and Surveillance of Immunodeficiency Disorders |
|
|
863 | (1) |
|
|
864 | (1) |
|
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
|
864 | (1) |
|
|
864 | (1) |
|
|
865 | (1) |
|
|
865 | (1) |
|
Clinical Applications of DNA Analysis |
|
|
865 | (1) |
|
|
865 | (1) |
|
|
866 | (2) |
|
|
868 | (1) |
|
|
868 | (1) |
|
Chapter 41 Chromosome Analysis Of Hematopoietic And Lymphoid Disorders |
|
|
869 | (18) |
|
|
870 | (1) |
|
|
870 | (1) |
|
Chromosome Structure and Morphology |
|
|
870 | (1) |
|
|
871 | (1) |
|
|
872 | (3) |
|
|
872 | (1) |
|
Harvest Procedure and Banding |
|
|
873 | (1) |
|
|
873 | (2) |
|
|
875 | (2) |
|
|
875 | (1) |
|
|
875 | (2) |
|
|
877 | (1) |
|
|
877 | (1) |
|
Cytogenetic Analysis of Hematopoietic and Lymphoid Disorders |
|
|
878 | (4) |
|
|
878 | (1) |
|
Chronic Myelogenous Leukemia |
|
|
879 | (1) |
|
Myeloproliferative Disorders Other Than CML |
|
|
880 | (1) |
|
|
880 | (1) |
|
Myelodysplastic Syndromes (MDSs) |
|
|
881 | (1) |
|
Acute Lymphoblastic Leukemia (ALL)/Lymphoma |
|
|
881 | (1) |
|
Lymphoma and Lymphoproliferative Disorders |
|
|
882 | (1) |
|
Bone Marrow Transplantation |
|
|
882 | (1) |
|
|
882 | (1) |
|
|
883 | (1) |
|
|
883 | (2) |
|
|
885 | (1) |
|
|
885 | (2) |
|
Chapter 42 Molecular Analysis Of Hematologic Diseases |
|
|
887 | (16) |
|
|
888 | (1) |
|
|
888 | (1) |
|
Overview of Molecular Technologies |
|
|
889 | (6) |
|
|
889 | (1) |
|
Nucleic Acid Amplification |
|
|
889 | (4) |
|
|
893 | (2) |
|
Direct DNA Sequence Analysis |
|
|
895 | (1) |
|
Clinical Applications of Molecular Diagnostics in Hematopathology |
|
|
895 | (4) |
|
|
897 | (1) |
|
|
897 | (2) |
|
|
899 | (1) |
|
Clinical Applications of Molecular Diagnosis in Hemostasis |
|
|
899 | (1) |
|
|
899 | (1) |
|
|
900 | (1) |
|
|
900 | (1) |
|
|
900 | (1) |
|
|
900 | (1) |
|
|
900 | (1) |
|
Methylenetetrahydrofolate Reductase (MTHFR) |
|
|
900 | (1) |
|
Von Willebrand Disease (VWD) |
|
|
900 | (1) |
|
|
900 | (1) |
|
|
901 | (1) |
|
|
902 | (1) |
|
|
902 | (1) |
|
SECTION NINE QUALITY ASSESSMENT |
|
|
903 | (19) |
|
Chapter 43 Quality Assessment In The Hematology Laboratory |
|
|
903 | (19) |
|
|
904 | (1) |
|
Test Coding and Reimbursement |
|
|
904 | (1) |
|
|
905 | (7) |
|
|
905 | (2) |
|
|
907 | (1) |
|
|
907 | (1) |
|
Method Evaluation/Instrument Comparison |
|
|
908 | (2) |
|
Reference Interval Determination |
|
|
910 | (1) |
|
|
911 | (1) |
|
|
912 | (2) |
|
|
912 | (1) |
|
Establishing Quality Control (QC) Limits |
|
|
912 | (1) |
|
Interpreting Quality Control Charts |
|
|
912 | (1) |
|
Bull's Testing Algorithm (Moving Averages) |
|
|
913 | (1) |
|
Monitoring Quality Control with Patient Samples |
|
|
913 | (1) |
|
Review of Patient Results |
|
|
914 | (4) |
|
|
914 | (4) |
|
|
918 | (1) |
|
|
918 | (1) |
|
|
919 | (1) |
|
|
920 | (1) |
|
|
921 | (1) |
|
|
|
Appendix A Answers to Review Questions |
|
|
922 | (10) |
|
Appendix B Hematopoietic and Lymphoid Neoplasms: Immunophenotypic and Genetic Features |
|
|
932 | (3) |
|
Appendix C 2008 WHO Classification of Hematologic, Lymphopoietic, Histiocytic/Dendritric Neoplasms |
|
|
935 | (3) |
Glossary |
|
938 | (34) |
Index |
|
972 | |